4 Mar 2020 10:11
04 March 2020
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application for admission to the Premium Segment of the Official List has been made to the Financial Conduct Authority and the London Stock Exchange for the following:
· Additional 30,000 for the existing Save As You Earn block listing;
· 70,000 for a new blocklisting in relation to Global Save As You Earn Plan 2018;
· 175,000 for a new blocklisting in relation to Long Term Incentive Plan 2017.
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on or around 6 March 2020.
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is a global veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.